Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 47

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 47
---
 summons, notice or document by mail (to the extent allowed under any
applicable statute or rule of court) to such party’s address set forth in the indenture will be effective service of process for any suit, action or other proceeding brought in any such court. The indenture will further provide that we, the
trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the courts specified above and
irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum. (Section 10.10)

33

DESCRIPTION OF WARRANTS We may issue warrants for the purchase of shares of our equity securities or of debt securities. We may issue warrants independently or together with other securities, and the warrants may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent. The following summary of material provisions of the warrants and warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants. The particular terms of any issue of warrants will be described in the prospectus supplement relating to the issue. Those terms may include:

| • |     | the number of shares of debt or equity securities purchasable upon the exercise of warrants to purchase such 
 securities and the price at which such number of shares may be purchased upon such exercise;                 |

| • |     | the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and        
 voting rights) of the series of preferred shares purchasable upon exercise of warrants to purchase preferred shares; |

| • |     | the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise 
 price for the warrants, which may be payable in cash, securities or other property;                            |

| • |     | the date, if any, on and after which the warrants and the related debt securities, preferred shares